1356962-87-2

Basic information

• Product Name: 3-(5-broMo-2-chloropyriMidin-4-yl)-1H-indole
• Synonyms: 3-(5-broMo-2-chloropyriMidin-4-yl)-1H-indole
• CAS NO: 1356962-87-2
• Molecular Formula: C₁₂H₇BrClN₃
• Molecular Weight: 308.56108
• Mol File: 1356962-87-2.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 533.8±40.0 °C(Predicted)
• Appearance: /
• Density: 1.697±0.06 g/cm3(Predicted)
• PKA: 14.32±0.30(Predicted)
• CAS DataBase Reference: 3-(5-broMo-2-chloropyriMidin-4-yl)-1H-indole(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(5-broMo-2-chloropyriMidin-4-yl)-1H-indole(1356962-87-2)
• EPA Substance Registry System: 3-(5-broMo-2-chloropyriMidin-4-yl)-1H-indole(1356962-87-2)

Safety Data

• Hazardous Substances Data: 1356962-87-2(Hazardous Substances Data)

Upstream product

• 120-72-9 indole 
• 36082-50-5 2,4-dichloro-5-bromopyrimidine 

Downstream Products

• 1356962-88-3 3-(5-Bromo-2-chloropyrimidin-4-yl)-1-tosyl-1H-indole 
• 1356963-07-9 5-Bromo-N-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-4-(1-tosyl-1H-indol-3-yl)pyrimidin-2-amine 
• 1624262-44-7 3-(5-bromo-2-chloropyrimidin-4-yl)-1-(phenylsulfonyl)-1H-indole 

Relevant articles and documents

AMINOPYRIMIDINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF

Provided herein are novel compounds, for example, compounds having a Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, for treating various cancer described herein, such as lung cancer (e.g., non-small cell lung cancer).

INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.